|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1999-9-7
|
|
pubmed:abstractText |
Combination antiretroviral therapy with ritonavir and saquinavir has established potent and durable activity on plasma viremia. CNS HIV infection may be sequestered from drug therapy that does not penetrate the blood-brain barrier. Penetration of these protease inhibitors into the cerebrospinal fluid (CSF) and CSF HIV RNA levels on such therapy has not been well described.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1525-4135
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
371-5
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10458617-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:10458617-Anti-HIV Agents,
pubmed-meshheading:10458617-CD4 Lymphocyte Count,
pubmed-meshheading:10458617-Cross-Sectional Studies,
pubmed-meshheading:10458617-Drug Therapy, Combination,
pubmed-meshheading:10458617-HIV Infections,
pubmed-meshheading:10458617-HIV-1,
pubmed-meshheading:10458617-Humans,
pubmed-meshheading:10458617-Patient Selection,
pubmed-meshheading:10458617-RNA, Viral,
pubmed-meshheading:10458617-Ritonavir,
pubmed-meshheading:10458617-Saquinavir,
pubmed-meshheading:10458617-Treatment Failure,
pubmed-meshheading:10458617-Treatment Outcome,
pubmed-meshheading:10458617-Viral Load,
pubmed-meshheading:10458617-Viremia
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.
|
|
pubmed:affiliation |
Department of Medicine, Ottawa Hospital, General Campus Ottawa, Ontario, Canada. skravcik@ogh.on.ca
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
